Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1interventionalRules rewrite

Phase 1: testing Surovatamig for Rheumatoid Arthritis

This open-label, Phase I study will assess the whether it is safe and how hard side effects are to live with of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

Official registry: https://clinicaltrials.gov/study/NCT07201558 · AstraZeneca · enrollment listed as 48

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Surovatamig. The registry lists allocation as randomized. This open-label, Phase I study will assess the whether it is safe and how hard side effects are to live with of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

They plan to enroll about 48 people at 34 sites. Taking part typically means an infusion or injection of a biologic plus check-ins.

Official title (unrewritten)

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

Interventions: Surovatamig

Primary outcome (registry wording): Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 65 Years
  • For RA participants, only:
  • Diagnosis of RA as defined by the 2010 EULAR/ACR classification criteria
  • Positive for ≥ 1 disease-specific autoantibody performed by the central laboratory
  • Moderate or severe disease activity defined as:
  • DAS28-a blood inflammation marker (CRP) \> 3.2 AND
  • 4 tender joints and ≥ 4 swollen joints
  • Diagnosis of SLE as defined by the 2019 EULAR/ACR classification criteria

Public study contact (from the registry)

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

34 listed

+ 28 sites outside the US on the same record

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseBethesda, Maryland
Immune System Related Kidney Disease

Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders. This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney.

NCT00001979 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

FAQ about this NCT record

Is NCT07201558 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07201558?

Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07201558?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary